OUR SCIENCE

Hillstream Oncology

powered by Tharimmune

Next Generation of Targeted Cancer Therapies

TH3215: Next-Generation Anti-HER2/ HER3 Bispecific Antibody

The ErbB family of cell surface proteins, notably HER2 (human epidermal growth factor receptor) and HER3, stands as one of the most significant targets in oncology. Over the years, the development of antibodies against HER2 has marked a pivotal milestone in cancer therapy, starting with the groundbreaking approval of HERCEPTIN® (trastuzumab) in 1998. Today, with innovative additions like PERJETA®, KADCYLA®, and PHESGO®, this family of therapeutics has amassed a remarkable $8.4 billion in sales for Roche/Genentech in 2022.

However, traditional approaches to targeting HER2 and HER3 often encounter limitations due to shared epitopes with trastuzumab. Here at our company, we’re proud to introduce TH3215, an anti-HER2/HER3 bispecific antibody that represents a paradigm shift in precision medicine. Developed at the Applied Biomedical Science Institute, TH3215 targets unique functional epitopes of HER2 and HER3, offering a novel approach to cancer therapy.

Through an exclusive option agreement with Hillstream, we’re poised to propel the development of TH3215 further, unlocking new possibilities in the treatment of HER2-positive cancers. With our commitment to innovation, we’re paving the way for next-generation therapeutics that hold the promise of improved outcomes for patients worldwide.

molecule 3
of all breast cancers are HER2 positive
15 %
recurrence within 10 years of initial diagnosis
20 %
bsAb products approved by the FDA
0
20%

of all breast cancers are HER2 positive

30%

recurrence within 10 years of initial diagnosis

11

bsAb products approved by the FDA

TH0059: Innovative Bispecific Antibody Drug Conjugates (ADCs)

Antibody Drug Conjugates (ADCs) have emerged as a revolutionary class of therapeutics, offering targeted delivery of potent chemotherapy directly to cancer cells. However, traditional ADCs targeting HER2 and HER3 face challenges due to shared epitopes with trastuzumab, limiting their efficacy.

Enter TH0059, our innovative solution built upon the TH3215 backbone. By targeting novel epitopes on HER2 while simultaneously inhibiting natural ligands to HER3, TH0059 represents a quantum leap forward in ADC design. Notably, our approach harnesses the potential bystander effect, allowing the toxin payload to eliminate surrounding cancerous tissue, thereby maximizing therapeutic efficacy.

With TH0059, we’re not only redefining the boundaries of precision oncology but also ushering in a new era of personalized cancer therapy. Through relentless innovation and a commitment to excellence, we’re dedicated to advancing the field of cancer therapeutics and improving outcomes for patients worldwide.

molecule 4
of colorectal cancers HER3 overexpression or activation
0 %
reduction in risk of death with HER2 chemotherapy regimen
0 %
year survival rate of 65% with HER3-positive breast cancer
0
60%

of colorectal cancers HER3 overexpression or activation

37%

reduction in risk of death with HER2 chemotherapy regimen

5

year survival rate of 65% with HER3-positive breast cancer

TH1940: Revolutionizing Anti-PD-1 Therapy with Undruggable Epitopes

Unlocking undruggable epitopes presents a formidable challenge in the realm of immunotherapy. Inspired by nature’s ingenuity, we’re proud to introduce HSB-1940, a groundbreaking knob domain platform.

Traditional antibodies often struggle to access challenging epitopes effectively. However, HSB-1940 leverages ultralong complementary determining region (CDR) H3 sequences, enabling precise targeting of novel epitopes with unparalleled efficiency. Drawing inspiration from the unique antigen recognition mechanisms of bovines, our approach overcomes the limitations of traditional antibody therapy.

With knob domains, we’re not only shrinking the size of antibody fragments but also expanding the scope of therapeutic possibilities. At our company, we’re committed to pushing the boundaries of innovation, offering new hope to patients with previously unaddressed targets. Through groundbreaking research and unwavering dedication, we’re reshaping the future of anti-PD-1 therapy and paving the way for a world where every patient has access to cutting-edge cancer treatments.

molecule 5
advanced cancers respond to anti-PD-1 therapies
20 %
PD-1 inhibitors ORR range from 10% to 40% in different tumor types.
10 %
The incidence of AEs can affect up to 70% receiving PD-1 inhibitors
0 %
40%

advanced cancers respond to anti-PD-1 therapies

40%

PD-1 inhibitors ORR range from 10% to 40% in different tumor types.

70%

The incidence of AEs can affect up to 70% receiving PD-1 inhibitors

Explore our Innovative Immunology Technology